The study, led by Henry Omar Herrera of Case Western Reserve University together with colleagues at University Hospitals Cleveland Medical Center and Albert Einstein College of Medicine, set out to answer a deceptively simple question. When Hispanic or Latino patients are diagnosed with psoriasis, what is their subsequent risk of developing new-onset metabolic conditions such as type 2 diabetes, hypertension, dyslipidemia, obesity-related disorders, and metabolic syndrome? The question matters because psoriasis is already recognized as an independent risk factor for metabolic disease in the general population, but the vast majority of the evidence base has been built on cohorts of European descent.

The biological rationale for the psoriasis-metabolism connection is well established. Psoriasis is driven by a sustained activation of the immune system, particularly T cells and inflammatory signaling molecules such as tumor necrosis factor alpha, interleukin-17, and interleukin-23. These cytokines do not confine their effects to the skin. They circulate systemically, promoting insulin resistance in muscle and liver tissue, altering lipid metabolism, and encouraging the low-grade vascular inflammation that underlies atherosclerosis. Over months and years, this chronic inflammatory state can tip patients toward the metabolic syndrome cluster of abdominal obesity, elevated triglycerides, low HDL cholesterol, high blood pressure, and impaired fasting glucose.

Hispanic and Latino populations in the United States carry a distinct baseline metabolic profile that makes this interaction especially consequential. National surveillance data cited by the authors show that Hispanic Americans experience higher rates of diabetes and several of its complications compared with non-Hispanic white Americans. Large epidemiological surveys, including the landmark JAMA analysis of diabetes prevalence by race and ethnicity from 2011 to 2016, have documented that the burden of diagnosed and undiagnosed diabetes is disproportionately heavy in this community. Layering the systemic inflammation of psoriasis on top of that elevated baseline risk creates a scenario in which even a modest additional inflammatory push could translate into a meaningful increase in new metabolic diagnoses.

Yet, as the authors and prior reviewers have noted, Hispanic and Latino patients with psoriatic disease have historically been a blind spot in the literature. A comprehensive review of psoriatic disease in the US Latino population published in the American Journal of Clinical Dermatology highlighted how little controlled data exist on disease presentation, treatment response, and comorbidity trajectories in this group. Dermatology registries and biologic trials tend to enroll predominantly white participants, which means that risk estimates derived from those datasets may simply not apply to other populations. Genetic ancestry, patterns of adipose tissue distribution, dietary and occupational factors, access to care, and differences in how aggressively comorbidities are screened for can all shift the relationship between skin inflammation and metabolic outcomes.

The retrospective cohort design of the new analysis reflects both the practicality and the limitations of studying these questions with real-world medical records. Rather than randomizing patients to interventions, the researchers looked backward through clinical data, identifying Hispanic or Latino patients with a diagnosis of psoriasis vulgaris and tracking whether they went on to receive new diagnoses of metabolic comorbidities during follow-up. Retrospective cohorts of this kind are powerful for generating incidence estimates and hypothesis-generating risk signals in populations that are rarely captured in prospective trials, but they depend on the completeness and accuracy of the underlying records, and they can be vulnerable to confounding by factors such as body mass index, medication use, and healthcare utilization patterns.

Why does this matter clinically? Dermatologists are increasingly viewed as the first line of defense against the systemic consequences of psoriasis. A patient who presents with plaques on the elbows and scalp is not just a cosmetic or comfort concern; that patient carries a quantifiably elevated lifetime risk of myocardial infarction, stroke, and diabetes. Guidelines from several dermatology societies now recommend that patients with moderate to severe psoriasis undergo periodic screening for metabolic syndrome components, including blood pressure, fasting glucose or hemoglobin A1c, and lipid panels. If Hispanic and Latino patients face a higher trajectory of new-onset metabolic disease after a psoriasis diagnosis, then screening intensity, lifestyle counseling, and early referral to primary care or endocrinology may need to be calibrated differently for this population.

The study also arrives at a moment when the demographics of psoriasis in the United States are shifting. Hispanic Americans represent a large and rapidly growing share of the national population, and psoriasis affects an estimated three percent of US adults overall. Simple arithmetic dictates that the absolute number of Hispanic and Latino individuals living with psoriatic disease will continue to climb. If the comorbidity burden in this group is systematically underestimated, health systems will be caught unprepared for a wave of cardiovascular and diabetic complications that could have been anticipated and, in part, prevented. Health disparities research of this type is therefore not merely academic; it is a matter of resource allocation, screening policy, and ultimately lives saved.

There are also important mechanistic questions raised by population-specific risk research. Adiposity patterns differ across ancestral groups, with some populations showing greater visceral fat deposition at the same body mass index, and visceral fat is a particularly potent source of the inflammatory adipokines that synergize with psoriasis-related cytokines. Genetic variants influencing both immune signaling and lipid metabolism vary in frequency across populations. Socioeconomic factors, including food environments, occupational stress, and barriers to consistent healthcare, further modulate the observed risk. Disentangling these strands requires exactly the kind of targeted cohort work that the Cleveland and Bronx-based team has begun, and it argues for larger, multi-center, prospective studies with granular data on ancestry, disease severity measured by body surface area or PASI scores, and longitudinal metabolic laboratory values.

For now, the practical message for clinicians and patients is clear. Psoriasis in Hispanic and Latino patients should prompt the same vigilance toward metabolic health that the field has learned to apply in other populations, and quite possibly more. Patients should be aware that their skin condition is connected to their heart and metabolic health, and that controlling systemic inflammation, maintaining a healthy weight, staying physically active, and keeping up with metabolic screening are all part of managing psoriasis in the twenty-first century. As the evidence base grows more inclusive, the hope is that risk prediction and preventive care will finally serve every population equally, rather than only those who have historically filled the clinical trials.

Subject of Research: Risk of new-onset metabolic comorbidities in Hispanic or Latino patients with psoriasis vulgaris

Article Title: Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis

Article References: Herrera, H. O., Nolasco, B., Sánchez-Feliciano, A., & Bordeaux, J. (2026). Risk of new-onset metabolic comorbidities in hispanic or latino patients with psoriasis vulgaris: a retrospective cohort analysis. Archives of Dermatological Research, 318(1), Article 512. https://doi.org/10.1007/s00403-026-04971-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04971-3

Keywords: psoriasis, psoriasis vulgaris, Hispanic health, Latino health, metabolic syndrome, type 2 diabetes, cardiovascular risk, dermatology, health disparities, retrospective cohort, chronic inflammation, comorbidities

The headline numbers reveal a striking asymmetry between absolute scale and population-adjusted rates. In 2023, China recorded approximately 103,000 pancreatic cancer cases, substantially more than the 66,000 cases documented in the United States. Yet when the researchers adjusted for age structure, the picture inverted: China’s age-standardized prevalence stood at 4.51 per 100,000 people, compared with 11.19 in the United States, and its age-standardized mortality rate was 4.97 per 100,000 against 9.56 in the American population. This contrast reflects the interplay of population size, demographic aging, and underlying exposure to risk factors, and it underscores why raw case counts alone can mislead when comparing disease burden across countries with very different demographic profiles.

Trends over time added further nuance to the comparison. Between 1990 and 2023, the absolute burden of pancreatic cancer grew in both countries, a trajectory shaped by aging populations, population growth, and shifting exposures to known and suspected risk factors. However, when the researchers examined age-standardized DALYs, a metric that corrects for changes in population size and age composition, they found that China experienced a slight decline of 0.15 percent, while the United States saw a modest increase of 0.12 percent. Though these percentage changes appear small, they point in opposite directions and suggest that the two nations may be traveling along different epidemiological paths, with China potentially benefiting from earlier stages of its demographic and lifestyle transition and the United States confronting the cumulative consequences of metabolic disease.

Age distribution emerged as another point of divergence. In China, the burden of pancreatic cancer peaked among people aged 60 to 74, whereas in the United States the peak had shifted to an older bracket, ages 70 to 84. This difference in age patterning has practical consequences for health systems. It means that in China, pancreatic cancer strikes a working-age and recently retired population, amplifying the socioeconomic cost of each case through lost productivity and years of life lost, while in the United States the disease increasingly concentrates among the very old, placing demands on geriatric oncology services, palliative care infrastructure, and long-term support systems for elderly patients and their families.

Perhaps the most consequential finding of the study concerns the changing hierarchy of modifiable risk factors. In the United States, high fasting plasma glucose has overtaken tobacco use as the leading attributable risk factor for pancreatic cancer DALYs. In China, high fasting glucose has risen to become a major contributor, now roughly comparable to tobacco in its population-attributable impact. The researchers measured this using population attributable fractions, or PAFs, which quantify the proportion of disease burden that could theoretically be eliminated if a specific risk factor were removed at the population level. The ascent of metabolic risk factors in both countries signals a fundamental shift in the prevention landscape, one that moves pancreatic cancer control increasingly into the domain of diabetes management, obesity prevention, and metabolic health.

This shift is biologically plausible and fits within a broader scientific understanding of pancreatic carcinogenesis. Chronic hyperglycemia, insulin resistance, and type 2 diabetes have been repeatedly associated with elevated pancreatic cancer risk in epidemiological studies, and the pancreas is an organ exquisitely sensitive to metabolic stress. At the same time, the decline of tobacco as the dominant attributable factor in the United States reflects decades of successful smoking control, a public health achievement that has reduced smoking prevalence substantially since the 1960s. The Chinese trajectory differs: smoking remains widespread, particularly among men, so tobacco continues to exert a heavy toll even as metabolic risk factors rise rapidly alongside economic development, dietary change, and increasing rates of overweight and diabetes.

The study also examined the socioeconomic dimensions of pancreatic cancer burden, and here the findings were sobering. Globally, the burden of the disease remained concentrated in regions with a high socio-demographic index, a composite measure of income, education, and fertility that serves as a proxy for overall development. More troubling still, absolute socioeconomic inequality in pancreatic cancer burden increased over the study period. This pattern suggests that as some populations gain access to better diagnostics, registration, and care, the measured and actual burden accumulates disproportionately among wealthier and more developed settings, while gaps between the best-off and worst-off regions widen rather than narrow. For a disease that is already difficult to diagnose early and harder still to treat, such inequities compound the challenge of mounting an effective global response.

The methodological backbone of the analysis deserves attention, because it illustrates how modern burden-of-disease research works. The Global Burden of Disease Study synthesizes data from vital registration systems, cancer registries, and modeling approaches to produce comparable estimates across countries and years, complete with 95 percent uncertainty intervals that convey the precision of each figure. By combining these estimates with population attributable fractions for individual risk factors, the researchers could rank the drivers of pancreatic cancer DALYs in each country and track how those rankings changed between 1990 and 2023. This framework transforms raw epidemiological surveillance into actionable intelligence, allowing policymakers to see not just how much disease exists but which modifiable exposures contribute most to it and how those contributions are evolving.

The research was led by investigators including Dr. Yifei Hu of the School of Public Health at Capital Medical University in Beijing and Dr. Wenming Wu of the Department of General Surgery at Peking Union Medical College Hospital, and it was funded by the Beijing Natural Science Foundation and the National Natural Science Foundation of China. The authors conclude that tailored, country-specific prevention strategies will be essential to curb the growing burden of pancreatic cancer in the coming decades, with particular emphasis on addressing the rising tide of metabolic risk factors. For the United States, that means treating glycemic control and diabetes prevention as cancer prevention, while for China it demands a dual strategy that confronts both the entrenched tobacco epidemic and the accelerating metabolic transition simultaneously.

The broader lesson of this study extends beyond two countries. Pancreatic cancer is projected to remain a leading cause of cancer death worldwide, and its resistance to early detection and treatment makes prevention the most powerful available lever. As populations age and metabolic diseases proliferate across the globe, the findings from China and the United States offer a preview of what many nations may face: a rising tide of pancreatic cancer whose risk profile is shifting from behavioral exposures like smoking toward metabolic conditions like hyperglycemia. Health systems that anticipate this shift, investing in diabetes prevention, metabolic screening, and equitable access to care, may be better positioned to blunt the impact of one of medicine’s deadliest diseases before its burden becomes unmanageable.

Subject of Research: Comparative burden and risk factors of pancreatic cancer in China and the United States, 1990–2023

Article Title: Pancreatic cancer burden rises in both China and the US, but patterns diverge

Article References: Pancreatic cancer burden rises in both China and the US, but patterns diverge. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, Global Burden of Disease, DALYs, high fasting glucose, tobacco use, China, United States, population attributable fraction, metabolic risk factors, age-standardized mortality, socioeconomic inequality, cancer prevention

The research team, led by Jie Wen of Shandong University and the North China University of Science and Technology Affiliated Hospital, enrolled participants between December 2020 and May 2022 at a tertiary reproductive medicine centre, with follow-up extending through December 2025. The cohort comprised 500 lean women and 1,000 women who were overweight or obese, a deliberate imbalance that gave the investigators statistical power to interrogate the heavier phenotype. Two primary endpoints anchored the analysis: the incidence of metabolic syndrome, defined by the Chinese Diabetes Society 2017 criteria, and the cumulative live-birth rate among the 973 patients who underwent assisted reproduction, encompassing 1,432 treatment cycles. The dual design allowed the researchers to capture both the metabolic and the reproductive faces of the syndrome within a single framework.

At baseline, the two phenotypes were already metabolically worlds apart. Overweight and obese participants had an average body-mass index of 29.54 kilograms per square metre, compared with 22.23 in the lean group, and their insulin resistance, measured by the homeostatic model assessment known as HOMA-IR, averaged 3.90 against 2.20. Most strikingly, metabolic syndrome was already present in 31.8 percent of the heavier women at enrolment but in essentially none of the lean group, just 0.2 percent. These figures reflect the well-established biology of the syndrome, in which adipose tissue, particularly visceral fat, amplifies insulin resistance, suppresses hepatic production of sex hormone-binding globulin, and drives the hyperandrogenism that characterises the condition.

The prospective findings were equally consequential. Over a median follow-up of 4.3 years, new-onset metabolic syndrome developed in 19.94 percent of the overweight or obese women compared with 9.22 percent of lean women, an adjusted hazard ratio of 2.33 with a 95 percent confidence interval of 1.66 to 3.27 and a p-value below 0.001. Incident type 2 diabetes followed the same pattern, occurring in 7.0 percent of the heavier group versus 2.6 percent of the lean group, a difference that reached statistical significance at p equals 0.001. In other words, even after accounting for age and other baseline characteristics, excess weight independently accelerated the march toward cardiometabolic disease in these young women, many of whom were still in their twenties and thirties.

Reproductive outcomes told an equally sobering story. Among the 973 women who pursued assisted reproductive technology, the cumulative live-birth rate stood at 70.49 percent for lean patients but only 52.84 percent for those who were overweight or obese. In patient-level logistic regression, this translated into an adjusted odds ratio of 0.46, with a 95 percent confidence interval of 0.34 to 0.62, meaning the odds of a live birth were cut by more than half. A complementary cycle-level analysis using generalised estimating equations, which properly accounts for multiple treatment cycles in the same patient, yielded an adjusted odds ratio of 0.56 with a confidence interval of 0.44 to 0.70. The consistency of these two analytical approaches strengthens the conclusion that the association is robust rather than an artefact of statistical modelling.

Pregnancy itself proved markedly riskier for the heavier phenotype. Gestational diabetes affected 23.49 percent of overweight or obese women who conceived, compared with 10.06 percent of lean women. Hypertensive disorders of pregnancy, which include pre-eclampsia and threaten both mother and fetus, occurred in 9.44 percent versus 2.83 percent. Macrosomia, the birth of an abnormally large infant that raises the risk of obstetric injury and later childhood obesity, was recorded in 11.65 percent versus 4.40 percent of births. All three differences were highly significant, with p-values at or below 0.001. Taken together, the data suggest that excess weight compounds the already elevated obstetric risk that accompanies the syndrome, creating a cascade of complications that begins before conception and extends through delivery.

Methodological rigour was a hallmark of the study. The investigators deployed Cox proportional-hazards regression for the time-to-event metabolic outcomes, generalised estimating equations for repeated-cycle reproductive data, and patient-level logistic regression for cumulative live birth. To guard against confounding, they ran sensitivity analyses using propensity-score matching and overlap weighting, techniques that re-balance the comparison groups on measured characteristics, and they repeated the metabolic syndrome analysis under alternative definitions, including those of the International Diabetes Federation. Subgroup analyses confirmed that the estimates held steady across age bands, Rotterdam phenotype classifications, and baseline insulin-resistance status, indicating that the findings are not confined to a narrow slice of the patient population.

Perhaps the most important message, however, lies in what the study says about lean patients. Although they fared far better than their heavier counterparts, lean women with the syndrome were not metabolically benign: nearly one in ten developed metabolic syndrome within the follow-up window, and about one in forty developed type 2 diabetes. This observation challenges the clinical habit of treating normal-weight patients as low-risk and dismissing them from metabolic surveillance. The underlying insulin resistance and endocrine dysfunction that define the syndrome can smoulder independently of adiposity, and the authors argue that this hidden burden justifies routine metabolic screening for all patients regardless of body size.

The study does carry the inherent limitations of retrospective design. Data were drawn from routinely collected clinical records at a single tertiary reproductive medicine centre, a setting that may over-represent women with more severe disease or greater fertility concerns, potentially limiting generalisability. Residual confounding by unmeasured lifestyle factors, such as diet, physical activity, and smoking, cannot be excluded, and the lean group’s near-total absence of baseline metabolic syndrome, while biologically plausible, underscores how phenotype selection can shape observed rates. Ethical approval was granted retrospectively for the completed observational dataset, and informed consent was obtained from all participants in accordance with the Declaration of Helsinki.

Even so, the clinical implications are hard to ignore. The authors conclude that care for women with the syndrome should be stratified by body-mass index, with intensified metabolic surveillance for those who are overweight or obese and structured pre-conception weight management offered as standard practice rather than optional advice. Given that the condition affects roughly one in ten women of reproductive age worldwide, and that assisted reproduction is increasingly the route to parenthood for many of them, the finding that excess weight halves the odds of a live birth carries enormous personal and public-health weight. The study, published open access on 4 October 2026 with the DOI 10.1186/s12902-026-02575-6, adds momentum to a growing movement to reframe the syndrome not merely as a fertility disorder but as a lifelong metabolic condition whose management begins long before the first fertility clinic visit.

Subject of Research: Long-term metabolic and reproductive outcomes by body-mass-index phenotype in polyendocrine metabolic ovarian syndrome

Article Title: Metabolic and reproductive outcomes in lean versus overweight/obese phenotypes of polyendocrine metabolic ovarian syndrome: a retrospective cohort study with long-term follow-up

Article References: Wen, J., Guo, R., & Zuo, Z. (2026). Metabolic and reproductive outcomes in lean versus overweight/obese phenotypes of polyendocrine metabolic ovarian syndrome: a retrospective cohort study with long-term follow-up. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02575-6

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02575-6

Keywords: polyendocrine metabolic ovarian syndrome, polycystic ovary syndrome, obesity, metabolic syndrome, insulin resistance, assisted reproductive technology, cumulative live-birth rate, gestational diabetes, type 2 diabetes, retrospective cohort study, body-mass index, reproductive medicine

The research, led by Nour Amin Elsahoryi of the University of Petra in Jordan together with colleagues across Jordan, Malaysia, Tunisia, Germany, and Bahrain, set out to do something unusually comprehensive: to phenotype night eating syndrome across body composition, blood chemistry, appetite-regulating hormones, psychological symptoms, and eating behavior, all within a single clinical cohort. The population studied was also notable. Middle Eastern populations remain dramatically underrepresented in eating disorder research, and this investigation offers one of the most detailed metabolic portraits of the condition in that region to date.

The team recruited eighty adults who had sought help for nocturnal eating concerns. The participants were young, with a median age of just twenty-one years, and predominantly female, making up eighty-five percent of the sample. Each volunteer underwent a battery of assessments: bioelectrical impedance analysis to measure body composition, fasting blood draws for biochemical assays, a twenty-four-hour dietary recall to capture eating patterns, and a suite of validated Arabic-language questionnaires covering mood, sleep, and eating behavior.

To classify participants, the researchers used the Night Eating Questionnaire, a widely applied screening instrument. Anyone scoring twenty-five or above was placed in the night eating syndrome screening-positive group, which amounted to thirty-eight people, or 47.5 percent of the cohort. The remaining forty-two participants formed the comparison group. This threshold-based approach allowed the investigators to compare the two clusters across dozens of biological and psychological variables, then apply rigorous statistical controls to ensure the differences they found were not statistical noise.

The metabolic contrasts were striking. Participants screening positive for the syndrome had a median body mass index of 27.80 kilograms per square meter, compared with 20.65 in the comparison group, and their median visceral fat level was more than double, at 14.00 versus 6.50. Visceral fat, the metabolically active fat wrapped around internal organs, is among the most dangerous forms of adiposity, strongly linked to insulin resistance and cardiovascular disease. Finding it elevated in a cohort whose median age is twenty-one is a warning sign that the metabolic consequences of disordered night eating may begin early in adult life.

The blood work told a consistent story. Leptin, the hormone released by fat cells that signals energy stores to the brain, was fifty-two percent higher in the night eating group. Insulin concentrations were fifty percent higher, and estimated insulin resistance, calculated using the homeostatic model assessment, was thirty-nine percent higher. Elevated leptin alongside increased fat mass suggests a state of leptin elevation consistent with greater adiposity rather than a primary signaling defect, but the insulin findings point toward genuine metabolic strain. Even more provocative were the inflammatory markers: C-reactive protein, a liver-produced sentinel of systemic inflammation, was fifty-eight percent higher, and interleukin-6, a cytokine that drives inflammatory signaling throughout the body, was fifty-one percent higher. All of these differences survived the Benjamini-Hochberg false-discovery-rate correction, a statistical procedure designed to keep false positives in check when many comparisons are made simultaneously.

The psychological and behavioral profile of the screening-positive group was equally concerning. Median scores for depression, anxiety, and stress, measured with the DASS-21 scales, were all significantly higher than in the comparison group, as were scores for emotional eating and insomnia severity. Every one of these differences remained statistically significant after multiplicity adjustment, with adjusted p-values at or below 0.002. This convergence of mood disturbance, poor sleep, and emotion-driven eating suggests that night eating syndrome sits at the intersection of mental health and metabolism, rather than belonging cleanly to either domain.

To identify which factors were independently associated with night eating status, the researchers ran an exploratory binary logistic regression, a technique that estimates the unique contribution of each variable while holding the others constant. Five factors emerged: emotional eating, smoking, body mass index, insomnia severity, and depressive-symptom severity. The picture that emerges is of a syndrome sustained by a web of interacting influences, where emotional distress drives eating, disrupted sleep reinforces abnormal eating rhythms, and increasing body weight feeds back into both the metabolic and psychological burden. Smoking, too, appeared as an independent correlate, hinting that health behaviors cluster in ways that compound risk.

The authors are careful, and rightly so, about what the study cannot show. Because every participant was assessed at a single point in time, the design is cross-sectional and cannot establish causality or temporal ordering. It is entirely possible that metabolic and inflammatory changes drive night eating, that night eating drives the metabolic changes, or that a third factor, such as chronic stress or circadian disruption, produces both. Elevated interleukin-6, for example, is known to influence both appetite regulation and sleep architecture, making it a plausible common pathway. Longitudinal studies that follow individuals over months and years will be needed to untangle the direction of these relationships, and the researchers explicitly call for such work.

Even with those caveats, the clinical implications are hard to ignore. If night eating syndrome is accompanied by measurable insulin resistance, visceral fat accumulation, and systemic inflammation in people barely old enough to have finished university, then early identification matters enormously. The findings support an integrated approach to care, one that combines emotional regulation support, smoking cessation, sleep-focused interventions, mental health treatment, and metabolic assessment when clinically indicated. They also underscore the need for culturally appropriate screening tools and care pathways in Middle Eastern populations, where evidence on eating disorders remains thin. What this study delivers is a detailed biological fingerprint of a condition too often dismissed as a simple habit, and it makes a compelling case that the kitchen light left on at midnight may be illuminating the early stages of a genuine metabolic-inflammatory disorder.

Subject of Research: Night eating syndrome and its metabolic, inflammatory, and psychological correlates in young adults

Article Title: Night eating syndrome as a metabolic-inflammatory disorder: comprehensive phenotyping through a cross-sectional analytical study in middle eastern young adults

Article References: Elsahoryi, N. A., Alhaj, O. A., Kaur, S., Trabelsi, K., Ammar, A., & Jahrami, H. (2026). Night eating syndrome as a metabolic-inflammatory disorder: comprehensive phenotyping through a cross-sectional analytical study in middle eastern young adults. Journal of Eating Disorders. https://doi.org/10.1186/s40337-026-01789-2

Image Credits: AI Generated

DOI: 10.1186/s40337-026-01789-2

Keywords: night eating syndrome, eating disorders, insulin resistance, leptin, inflammation, visceral fat, emotional eating, insomnia, depression, obesity, Middle East, metabolic health

The study, known as the Tianshan Community Cohort, enrolled participants between January 2019 and December 2023 through 12,520 primary healthcare institutions across the Xinjiang Uyghur Autonomous Region, a territory of roughly 1.66 million square kilometers. The cohort is ethnically diverse, comprising approximately 53 percent Uyghur, 33 percent Han, and 14 percent other minority participants, with 52 percent women. Annual health examinations mandated by China’s National Basic Public Health Services Program provided repeated measurements of six metabolic risk factors: obesity, hepatic steatosis, hypertension, hyperlipidemia, diabetes, and renal dysfunction. Cardiovascular events were objectively ascertained from inpatient records at 163 tertiary hospitals and 63 traditional Chinese medicine hospitals, coded according to the tenth revision of the International Classification of Diseases.

Among the 7,513,828 participants included in the primary analysis, who had a mean age of 44.4 years, the researchers tracked 669,995 incident cardiovascular events over a median follow-up of 4.5 years, including 442,120 cases of coronary heart disease and 398,300 strokes. As expected, cardiovascular incidence rose steeply with age, from 1.8 per 1,000 person-years in adults under 40 to 107.5 per 1,000 person-years among the very old. But the striking discovery was not the raw incidence; it was how the strength of the link between each metabolic abnormality and cardiovascular risk transformed across the age spectrum, with a rigor that had never before been achieved at this scale.

The central message is that metabolic abnormalities exert their most potent cardiovascular effects in young adults, and the strength of these associations steadily attenuates with advancing age. Hypertension showed the most dramatic pattern: in adults under 40, it was associated with a 3.60-fold increase in cardiovascular risk, but in those aged 80 and older, the hazard ratio fell to just 1.21. Diabetes showed a similar attenuation, from a hazard ratio of 2.48 in the youngest group to 1.31 in the oldest, as did hyperlipidemia, which fell from 1.65 to 1.05, and renal dysfunction, from 1.69 to 1.12. Notably, hypertension in young adults carried an exceptionally strong association with stroke specifically, with a hazard ratio of 4.84. When multiple metabolic abnormalities coexisted, the risk compounded: young adults with three or more risk factors had a 3.16-fold higher cardiovascular risk compared with metabolically healthy peers, whereas the excess risk among the very old with equivalent multimorbidity was only 1.50-fold.

The study also uncovered a striking age-dependent sexual dimorphism in metabolic health. In young adulthood, women enjoyed a clear metabolic advantage, being more likely to be metabolically normal and less likely to carry three or more simultaneous metabolic abnormalities. However, this female advantage reversed around age 45, when women became less likely to be metabolically normal than men, and a second reversal occurred around age 50, when the prevalence of multimorbidity in women surpassed that of men. The underlying factors crossed over at different ages: obesity and hepatic steatosis became more prevalent in women around age 40, hypertension around 50, and hyperlipidemia around 55. The researchers suggest that reproductive transitions, pregnancy-related hormonal shifts, childrearing-related lifestyle changes, and the perimenopausal reshaping of body composition likely drive this midlife reversal, making women a uniquely vulnerable population during this period.

Sex also mattered for the strength of metabolic risk itself. In adults under 40, hypertension was associated with a stronger cardiovascular impact in women than in men, with a hazard ratio for stroke of 6.41 in young women compared with 4.22 in young men, a clinically meaningful disparity that the researchers flagged using a predefined ratio-of-hazard-ratios threshold. Conversely, renal dysfunction carried a stronger cardiovascular penalty for men than women in the two youngest age groups. These sex-specific patterns largely faded in older groups, suggesting that the physiological vulnerability of young women to hypertension-related vascular damage has been substantially underappreciated in a literature dominated by middle-aged and elderly cohorts.

To translate individual risk into population impact, the team calculated population attributable fractions, the proportion of cardiovascular disease cases that could be attributed to each metabolic factor, using a method that permutes each risk factor through every possible position in the statistical hierarchy to account for correlations and shared causal pathways. The combined metabolic burden showed an inverted U-shaped pattern across the lifespan, peaking in midlife at 37.89 percent among adults aged 40 to under 60, compared with 29.78 percent in young adults, 25.24 percent in those aged 60 to 80, and 15.85 percent in the very old. Obesity was the single largest contributor to cardiovascular burden in every age group, potentially explaining between 6.07 and 11.86 percent of incident cardiovascular cases across adulthood, followed by hypertension and hepatic steatosis. For coronary heart disease, obesity’s attributable fraction reached 13.91 percent in the middle-aged group, while for stroke, hypertension was the predominant contributor at every age. The researchers attribute obesity’s outsized regional prevalence partly to northwestern China’s distinctive climate, ethnic composition, and dietary habits, and they argue that its dual role as an upstream driver of other metabolic disorders makes obesity prevention the most consequential public health lever available.

Perhaps the most actionable finding came from analyzing what happens when metabolically abnormal people change their metabolic state. Among 3,712,053 participants with at least one metabolic risk factor at baseline, the researchers tracked transitions between the first and second health examinations, separated by a median of roughly one year. The results showed a clear dose-response relationship: each additional risk factor gained increased cardiovascular risk, and each one lost decreased it. Critically, the benefit of improvement was strongly age-dependent. Young adults who brought three or more metabolic risk factors under control within about a year experienced a 55 percent lower subsequent cardiovascular risk, compared with only a 17 percent reduction among the very old. The authors interpret this asymmetry through the lens of disease biology: metabolic derangements in the young are typically nascent and largely reversible, with minimal cumulative end-organ damage, whereas in the very old, metabolic control often represents long-term maintenance rather than true reversal, frequently accompanied by multimorbidity and polypharmacy.

The time-series analysis of 1,649,758 participants with five consecutive annual examinations added an alarming temporal dimension. In the youngest age group, obesity prevalence climbed from 36.0 percent in 2019 to 48.5 percent in 2023, while the proportion of metabolically normal individuals fell from 50.9 percent to 38.8 percent in just five years, a pace of deterioration far exceeding that seen in older groups. The authors note that metabolic abnormalities in young adults are chronically under-recognized and under-treated, and that without prompt intervention these abnormalities can progress into a self-reinforcing vicious cycle of insulin resistance and inflammation. In a region where cardiovascular disease causes an estimated 19.2 million deaths and 437 million disability-adjusted life years globally each year, and where 42 percent of incident cardiovascular cases in China are attributable to four major metabolic risk factors, the implications are stark.

Taken together, the study argues for a fundamental reallocation of preventive attention toward people under 60, and particularly toward young adults, who have been almost entirely absent from the evidence base that shapes current guidelines. Despite the persistently high metabolic burden in older adults, the window of maximal cardiovascular benefit from metabolic management appears confined to early and middle adulthood. The findings also call for age-specific and gender-sensitive strategies: intensified screening for hypertension in young women, obesity control as the universal top priority, and vigilant monitoring of midlife women as their metabolic advantage erodes through reproductive and menopausal transitions. The researchers acknowledge limitations, including the use of an indirect index rather than imaging to define hepatic steatosis, the absence of systematic medication data, self-reported lifestyle covariates, and the relatively short five-year follow-up, but extensive sensitivity analyses, including competing-risk regression, landmark analyses, and multiple imputation, consistently supported the primary conclusions. As the dual epidemics of youthful metabolic deterioration and population aging accelerate, this unprecedented cohort provides both a warning and a roadmap: the earlier metabolic health is restored, the greater the lifetime cardiovascular dividend.

Subject of Research: Metabolic risk factors and their age- and sex-specific impact on cardiovascular disease across the adult lifespan

Article Title: A landscape of metabolic burden and its cardiovascular impact across the adult lifespan: a prospective cohort study of 7.5 million people in Northwestern China

Article References: Liu, Z.-Y., Yang, J., Lyu, J.-Q., Miao, M.-Y., Qin, L.-Q., Wang, H.-P., Wan, Z., Huang, Q., Tao, J., Yang, Y., Di, Q., Yang, Y., Gu, K., & Chen, G.-C. (2026). A landscape of metabolic burden and its cardiovascular impact across the adult lifespan: a prospective cohort study of 7.5 million people in Northwestern China. The Lancet Regional Health – Western Pacific, 74, Article 101986. https://doi.org/10.1016/j.lanwpc.2026.101986

Image Credits: AI Generated

DOI: 10.1016/j.lanwpc.2026.101986

Keywords: cardiovascular disease, metabolic risk factors, obesity, hypertension, diabetes, hepatic steatosis, renal dysfunction, population attributable fraction, young adults, sex differences, prospective cohort, China